ANI Pharmaceuticals, Inc. ANIP
Set alert
70.67 USD 0.00 0.00%
At close · Nov 2
70.67 0.00 0.00%
After hours · Nov 2, 4:00 PM ET
Day range unavailable
69.58 52-week range 95.57
- YTD
- -10.48%
- 1 year
- -22.00%
- Open
- —
- Prev close
- 70.67
- Mkt cap
- 1.62B
- Vol
- 0
- Avg vol
- 389.13K
- EPS
- 4.54
- P/E
- 15.57
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- 6.98
- Beta
- 0.47
- Short ratio
- 8.21
- Inst. own
- 107.19%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 72.95
- 200-d avg
- 77.65
- 1y target
- 105.78
Analyst view
Consensus: buy
Buy
Price target (mean) 105.78 +49.7% upside
Now 70.67
- Target (low)
- 85.00
- Target (mean)
- 105.78
- Target (high)
- 121.00
Ratings (0m) 9 7 buy · 2 hold · 0 sell
- Strong buy3
- Buy4
- Hold2
- Sell0
- Strong sell0
Recommendation trend
- This month 9
- 1 month ago 9
- 2 months ago 8
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 2.18 | 2.02 – 2.33 | 2.04 | +6.9% | 280.20M | +23.0% | 9 |
| Next quarter | 2.82 | 2.57 – 2.97 | 2.33 | +21.0% | 319.27M | +29.2% | 9 |
| Current year | 9.26 | 9.17 – 9.37 | 7.89 | +17.4% | 1.10B | +24.9% | 9 |
| Next year | 10.13 | 9.46 – 10.47 | 9.26 | +9.3% | 1.22B | +10.8% | 9 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 23, 2026 | Oppenheimer | Initiated | — | Perform |
| Aug 10, 2026 | Guggenheim | Maintained | Buy | Buy |
| Aug 10, 2026 | Canaccord Genuity | Maintained | Hold | Hold |
| Jul 17, 2026 | Canaccord Genuity | Initiated | — | Hold |
| Jul 10, 2026 | Guggenheim | Reiterated | Buy | Buy |
| Jan 16, 2026 | Guggenheim | Maintained | Buy | Buy |
| Dec 9, 2025 | Barclays | Initiated | — | Overweight |
| Nov 10, 2025 | Guggenheim | Maintained | Buy | Buy |
| Oct 9, 2025 | Truist Securities | Maintained | Hold | Hold |
| Sep 24, 2025 | JP Morgan | Maintained | Overweight | Overweight |
| Sep 17, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Sep 8, 2025 | Guggenheim | Maintained | Buy | Buy |
| Aug 11, 2025 | Truist Securities | Maintained | Hold | Hold |
| Aug 8, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Jul 10, 2025 | HC Wainwright & Co. | Initiated | — | Buy |
| May 12, 2025 | Guggenheim | Reiterated | Buy | Buy |
| Apr 21, 2025 | Truist Securities | Maintained | Hold | Hold |
| Apr 11, 2025 | Guggenheim | Reiterated | Buy | Buy |
| Mar 17, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Mar 14, 2025 | Jefferies | Initiated | — | Buy |
| Mar 12, 2025 | JP Morgan | Initiated | — | Overweight |
| Mar 5, 2025 | Guggenheim | Maintained | Buy | Buy |
| Mar 3, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Dec 11, 2024 | Leerink Partners | Initiated | — | Outperform |
| Nov 11, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Oct 22, 2024 | Truist Securities | Maintained | Hold | Hold |
| Oct 11, 2024 | Piper Sandler | Initiated | — | Overweight |
| Sep 18, 2024 | Raymond James | Maintained | Outperform | Outperform |
| Sep 17, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Sep 11, 2024 | Truist Securities | Downgrade | Buy | Hold |